 | • レポートコード：MRC2303B049 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の希少神経疾患治療市場規模が予測期間中に年平均8.6％上昇すると推測されています。本調査書では、希少神経疾患治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤種類別（生物製剤、低分子化合物）分析、投与形態別（注射剤、経口剤、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、US WorldMeds LLC (Solstice Neurosciences LLC)、CSL Ltd、Merz Pharma GmbH & Co. KGaA、Aquestive Therapeutics Inc.、Kedrion Biopharma Inc.、Bayer AG、Pfizer Inc.、Novartis AG、Merck & Co. Inc. (EMD Serono Inc.)などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の希少神経疾患治療市場規模：薬剤種類別 - 生物製剤の市場規模 - 低分子化合物の市場規模 ・世界の希少神経疾患治療市場規模：投与形態別 - 注射剤における市場規模 - 経口剤における市場規模 - その他投与形態における市場規模 ・世界の希少神経疾患治療市場規模：地域別 - 北米の希少神経疾患治療市場規模 アメリカの希少神経疾患治療市場規模 カナダの希少神経疾患治療市場規模 メキシコの希少神経疾患治療市場規模 … - ヨーロッパの希少神経疾患治療市場規模 ドイツの希少神経疾患治療市場規模 イギリスの希少神経疾患治療市場規模 フランスの希少神経疾患治療市場規模 … - アジア太平洋の希少神経疾患治療市場規模 中国の希少神経疾患治療市場規模 日本の希少神経疾患治療市場規模 インドの希少神経疾患治療市場規模 … - 南米/中東の希少神経疾患治療市場規模 南アフリカの希少神経疾患治療市場規模 ブラジルの希少神経疾患治療市場規模 アルゼンチンの希少神経疾患治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The rare neurological disease treatment market is expected to register a CAGR of 8.6% during the forecast period.
The COVID-19 pandemic represents an international health crisis that is challenging to all governments. Health practitioners in different fields must guide people and governments to achieve safe health practices. In June 2020, the World Health Organization issued the results of a survey conducted by 155 countries during the three weeks of May 2020, which showed that the prevention and treatment services of various chronic diseases, including various rare neurological diseases such as amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, and Huntington’s disease, were severely disrupted, becoming a significant concern as people living with chronic diseases are at higher risk of severe COVID-19 related illness and death. As per the study titled “Rare neurological disorder documented following COVID-19 vaccination”, published in June 2021, the frequency of Guillain-Barre syndrome in India and England is estimated to be up to 10 times greater than expected after taking the COVID-19 vaccine. Thus, the COVID-19 pandemic has significantly impacted the market’s growth.
The rising prevalence of rare neurological diseases, increasing R&D procedures for treating neurological diseases, and the growing government policies worldwide to create awareness for these diseases may drive the rare neurological diseases treatment market.
There are about 5,000–8,000 rare diseases. Some neurological disorders include reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Creutzfeldt Jakob Disease, agnosia, Aicardi syndrome, and Aicardi-Goutieres syndrome. As per the report titled “Prevalence and incidence of rare diseases: Bibliographic data”, published in January 2022, the prevalence of chronic inflammatory demyelinating polyneuropathy is 3.7 in Europe. However, the diagnosis of rare neurological diseases involves several barricades, such as a lack of awareness about rare neurological diseases within the population. Rare diseases are creating huge healthcare and economic burden worldwide.
The National Organization for Rare Disorders (NORD) Report 2019 estimates that around 7,000 known rare diseases lead to remarkable morbidity and mortality in 25 million affected Americans. In addition, about one-third of these are thought to include neurological components and symptoms. However, the high cost of treatment is expected to hinder the growth of the rare neurological disease treatments market.
Rare Neurological Disease Treatment Market Trends
The Small Molecules Segment is Expected to Hold a Major Share in the Rare Neurological Disease Treatment Market
The small molecules segment holds a significant share in the rare neurological disease treatment market. It is anticipated to show a similar trend over the forecast period due to the higher cost of biological drugs.
As per the report titled “Peer support for the Huntington’s community…by the Huntington’s community, Huntington’s Community Connect “, published in December 2020, over 1,800 people have Huntington’s disease in Australia, and approximately 9,000 individuals are at risk of developing the disease. Similarly, a very high concentration of Huntington’s disease has been found in Venezuela, where the prevalence is about 700 per 100,000 population. According to the study titled ‘Biologics versus small molecules: Drug costs and patient access in 2021’ published in March 2021 in ‘Science Direct’, the market for small molecules is rapidly expanding. Small molecules are increasingly being used to treat chronic disorders and continue to dominate the pharmaceutical business while being more impacted by policy implementation than biologics, which are still relatively new in healthcare. Therefore, the rising adoption of small molecules in treating chronic diseases like rare neurological disorders is expected to drive the small molecule drug discovery market.
Moreover, the segment’s growth is contributed largely by collaboration among different market players for the research and discovery of small molecules for neurological diseases. For instance, in July 2021, Servier and Nymirum entered a strategic collaboration to identify and develop RNA-modulatory drugs to treat neurological diseases. Under the collaboration agreement, Nymirum will leverage its proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) to discover novel small molecule therapeutics for multiple neurological targets.
Increasing incidences of rare neurological diseases worldwide, increasing focus on fast-track approvals, technological advancements, and growing awareness regarding early diagnosis of rare neurological diseases are the key factors driving the small molecules segment.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a major share in the rare neurological disease treatment market due to the availability of reimbursement, growing incidence of rare neurological diseases, and increasing R&D in the region. As per the data published by the Center for Rare Neurological Disease Research in January 2021, rare neurological diseases affect approximately 200,000 individuals in the United States.
Additionally, the launch of new treatments for treating these diseases, such as Huntington’s disease, may drive the market. For instance, in December 2021, Novartis received approval from the US Food and Drug Administration (FDA) for Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s disease (HD). Moreover, the last day of February is celebrated as Rare Disease Day every year to raise awareness among policymakers and the public about rare diseases and their impact on patients’ lives. In February 2022, this day was celebrated to raise awareness about rare diseases, the people affected, and the collaborations by the National Institute of Health (NIH) that address scientific challenges and advance research for new treatments. Thus, these programs may help raise awareness regarding rare neurological diseases in the country, thus driving the demand for their treatment in the country.
Furthermore, increasing healthcare spending and the presence of well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent.
Rare Neurological Disease Treatment Market Competitor Analysis
The rare neurological disease treatment market is consolidated. The market consists of a few significant players that dominate the market, including CSL Ltd, Kedrion Biopharma Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics Inc., Bayer AG, Pfizer Inc., Novartis AG, Merck & Co. Inc. (EMD Serono Inc.), and Jazz Pharmaceuticals PLC.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Rare Neurological Diseases
4.2.2 Promising Pipeline Drugs for Treatment of Rare Neurological Diseases
4.2.3 Favorable Government Policies Worldwide for Speeding up Diagnostic Processes
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Type
5.1.1 Biologics
5.1.2 Small Molecules
5.2 By Mode of Administration
5.2.1 Injectables
5.2.2 Oral
5.2.3 Other Modes of Administration
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 US WorldMeds LLC (Solstice Neurosciences LLC)
6.1.2 CSL Ltd
6.1.3 Merz Pharma GmbH & Co. KGaA
6.1.4 Aquestive Therapeutics Inc.
6.1.5 Kedrion Biopharma Inc.
6.1.6 Bayer AG
6.1.7 Pfizer Inc.
6.1.8 Novartis AG
6.1.9 Merck & Co. Inc. (EMD Serono Inc.)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS